BioSpace

Roche expands obesity R&D footprint with Rona deal worth $1B+

Roche has gained access to a genetic obesity approach from China's Rona Therapeutics for up to $100 million in upfront and near-term payments.

By BioSpace

1 min read
Roche expands obesity R&D footprint with Rona deal worth $1B+
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights